Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Michele Iudici. (2017) What should clinicians know about the use of glucocorticoids in systemic sclerosis?. Modern Rheumatology 27:6, pages 919-923.
Read now
Read now
Gabriele Valentini & Marco Matucci Cerinic. (2008) Anti-inflammatory New trends in the treatment of the patient with systemic sclerosis. Expert Opinion on Emerging Drugs 13:2, pages 227-236.
Read now
Read now
L. G. Gøransson, C. Brodin, P. Øgreid, E. A. M. Janssen, P. R. Romundstad, L. Vatten, K. Wildhagen, K. Kjellevold & R. Omdal. (2008) Intravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: morbidity and mortality. Scandinavian Journal of Rheumatology 37:2, pages 130-134.
Read now
Read now
Thorsten M Olski & Nicolas Hunzelmann. (2007) Immunosuppressive and antifibrotic therapy of systemic sclerosis. Expert Review of Dermatology 2:2, pages 203-215.
Read now
Read now
Articles from other publishers (26)
Caroline S. Grange & Annika Smith. 2024. Obstetric Anesthesia and Uncommon Disorders. Obstetric Anesthesia and Uncommon Disorders
421
442
.
Corrado Campochiaro, Yannick Allanore, Yolanda Braun-Moscovici, Marco Matucci-Cerinic & Alexandra Balbir-Gurman. (2024) Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?. Autoimmunity Reviews 23:1, pages 103439.
Crossref
Crossref
Mădălina Dudău, Cristina Alexandru, Florin Bobircă, Ancuţa Ioan, Mihai Bojincă & Anca Bobircă. (2023) Treatment of interstitial lung disease in systemic sclerosis. Medic.ro 1:151, pages 21.
Crossref
Crossref
Dijana Perković, Marin Petrić, Ivona Božić, Katarina Borić, Daniela Marasović Krstulović, Mislav Radić & Dušanka Martinović Kaliterna. (2020) Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis. Wiener klinische Wochenschrift 133:19-20, pages 1070-1075.
Crossref
Crossref
Martin Aringer & Gabriela Riemekasten. (2021) Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. Best Practice & Research Clinical Rheumatology 35:3, pages 101672.
Crossref
Crossref
Whitney A. High. 2021. Comprehensive Dermatologic Drug Therapy. Comprehensive Dermatologic Drug Therapy
209
221.e5
.
Boyang Zheng, Marie Hudson, Mianbo Wang, Murray Baron, Janet E. Pope, Murray Baron, Marie Hudson, Geneviève Gyger, Maggie J. Larché, Nader A. Khalidi, Ariel Masetto, Evelyn Sutton, David Robinson, Tatiana S. Rodriguez-Reyna, Nancy Maltez, Doug Smith, Carter Thorne, Alena Ikic, Paul R. Fortin & Marvin J. Fritzler. (2020) Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). Arthritis Research & Therapy 22:1.
Crossref
Crossref
Kensuke Suga, Hiroyuki Yamashita, Yuko Takahashi, Daisuke KatagiriFumihiko HinoshitaHiroshi Kaneko. (2020) Therapeutic efficacy of combined glucocorticoid, intravenous cyclophosphamide, and double-filtration plasmapheresis for skin sclerosis in diffuse systemic sclerosis. Medicine 99:10, pages e19301.
Crossref
Crossref
Rebecca B Blank, Ogonna Kenechi Nwawka, Anna A Yusov & Jessica K Gordon. (2018) Inflammatory arthritis in systemic sclerosis: What to do?. Journal of Scleroderma and Related Disorders 4:1, pages 3-16.
Crossref
Crossref
David R. Pearson, Victoria P. Werth & Lisa Pappas-Taffer. (2018) Systemic sclerosis: Current concepts of skin and systemic manifestations. Clinics in Dermatology 36:4, pages 459-474.
Crossref
Crossref
Jonathan Paek & Shobana Chandrasekhar. 2018. Consults in Obstetric Anesthesiology. Consults in Obstetric Anesthesiology
579
582
.
Teresa Bretones, Manuel Herruzo, Rafael Colman & William Delgado. (2017) Esclerosis sistémica: una posibilidad a tener en cuenta. Cardiocore 52:4, pages 168-170.
Crossref
Crossref
Nicoletta Del Papa & Eleonora Zaccara. (2015) From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis. Best Practice & Research Clinical Rheumatology 29:6, pages 756-769.
Crossref
Crossref
Michele Iudici, Giovanna Cuomo, Serena Vettori, Marialuisa Bocchino, Alessandro Sanduzzi Zamparelli, Salvatore Cappabianca & Gabriele Valentini. (2015) Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. Seminars in Arthritis and Rheumatism 44:4, pages 437-444.
Crossref
Crossref
Michele Iudici, Serena Fasano, Daniela Iacono, Barbara Russo, Giovanna Cuomo & Gabriele Valentini. (2013) Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clinical Rheumatology 33:2, pages 153-164.
Crossref
Crossref
Whitney A. High. 2013. Comprehensive Dermatologic Drug Therapy. Comprehensive Dermatologic Drug Therapy
212
227.e4
.
Gerald Trang, Russell Steele, Murray Baron & Marie Hudson. (2010) Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatology International 32:3, pages 645-653.
Crossref
Crossref
Abhishek Abhishek, Ramin Yazdani, Fiona Pearce, Marian Regan, Ken Lim, Richard Hubbard & Peter Lanyon. (2011) Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide. Clinical Rheumatology 30:8, pages 1099-1104.
Crossref
Crossref
Cecilia Chighizola, Voon H Ong & Christopher P Denton. (2011) Cyclophosphamide as disease-modifying therapy for scleroderma: pros and cons. International Journal of Clinical Rheumatology 6:2, pages 219-230.
Crossref
Crossref
Diogo S. Domiciano, Eloisa Bonfá, Claudia T. L. Borges, Ronaldo A. Kairalla, Vera L. Capelozzi, Edwin Parra & Romy Beatriz Christmann. (2010) A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clinical Rheumatology 30:2, pages 223-229.
Crossref
Crossref
Guillaume Bussone, Alice Berezné & Luc Mouthon. (2009) Complications infectieuses de la sclérodermie systémique. La Presse Médicale 38:2, pages 291-302.
Crossref
Crossref
Ulf Muller-Ladner. 2009. Genomic and Personalized Medicine. Genomic and Personalized Medicine
1155
1168
.
Anthony J. Gerbino, Christopher H. Goss & Jerry A. Molitor. (2008) Effect of Mycophenolate Mofetil on Pulmonary Function in Scleroderma-Associated Interstitial Lung Disease. Chest 133:2, pages 455-460.
Crossref
Crossref
Ivan Foeldvari. 2007. Pediatrics in Systemic Autoimmune Diseases. Pediatrics in Systemic Autoimmune Diseases
107
118
.
T. Krieg & K. Takehara. (2006) Skin disease: a cardinal feature of systemic sclerosis. Rheumatology 48:suppl_3, pages iii14-iii18.
Crossref
Crossref
M. Matucci-Cerinic, V. Steen, P. Nash & E. Hachulla. (2006) The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatology 48:suppl_3, pages iii8-iii13.
Crossref
Crossref